Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barry Miller

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
American Journal of Respiratory and Critical Care Medicine|December 16, 2006
Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthmaJohan D Boot, Sanne de Haas, Svetlana Tarasevych, et al.
Emerging Infectious Diseases|July 14, 2006
Tickborne arbovirus surveillance in market livestock, Nairobi, KenyaRosemary Sang, Clayton Onyango, John Gachoya, et al.
The American Journal of Tropical Medicine and Hygiene|August 5, 2010
Rift Valley fever virus epidemic in Kenya, 2006/2007: the entomologic investigationsRosemary Sang, Elizabeth Kioko, Joel Lutomiah, et al.
The New England Journal of Medicine|March 6, 2023
Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial HypertensionMarius M Hoeper, David B Badesch, H Ardeschir Ghofrani, et al.
The European Respiratory Journal|January 30, 2025
Efficacy and safety of the activin signalling inhibitor, sotatercept, in a pooled analysis of PULSAR and STELLAR studiesMarius M Hoeper, Mardi Gomberg-Maitland, David B Badesch, et al.
Neurology|May 11, 2022
Randomized Phase 2 Study of ACE-083 in Patients With Charcot-Marie-Tooth DiseaseFlorian P Thomas, Thomas H Brannagan, Russell J Butterfield, et al.
The New England Journal of Medicine|September 30, 2025
Sotatercept for Pulmonary Arterial Hypertension within the First Year after DiagnosisVallerie V McLaughlin, Marius M Hoeper, David B Badesch, et al.
The New England Journal of Medicine|April 1, 2025
Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for DeathMarc Humbert, Vallerie V McLaughlin, David B Badesch, et al.
Muscle & Nerve|April 16, 2022
Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophyJeffrey M Statland, Craig Campbell, Urvi Desai, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
American Journal of Respiratory and Critical Care Medicine|December 16, 2006
Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthmaJohan D Boot, Sanne de Haas, Svetlana Tarasevych, et al.
Emerging Infectious Diseases|July 14, 2006
Tickborne arbovirus surveillance in market livestock, Nairobi, KenyaRosemary Sang, Clayton Onyango, John Gachoya, et al.
The American Journal of Tropical Medicine and Hygiene|August 5, 2010
Rift Valley fever virus epidemic in Kenya, 2006/2007: the entomologic investigationsRosemary Sang, Elizabeth Kioko, Joel Lutomiah, et al.
The New England Journal of Medicine|March 6, 2023
Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial HypertensionMarius M Hoeper, David B Badesch, H Ardeschir Ghofrani, et al.
The European Respiratory Journal|January 30, 2025
Efficacy and safety of the activin signalling inhibitor, sotatercept, in a pooled analysis of PULSAR and STELLAR studiesMarius M Hoeper, Mardi Gomberg-Maitland, David B Badesch, et al.
Neurology|May 11, 2022
Randomized Phase 2 Study of ACE-083 in Patients With Charcot-Marie-Tooth DiseaseFlorian P Thomas, Thomas H Brannagan, Russell J Butterfield, et al.
The New England Journal of Medicine|September 30, 2025
Sotatercept for Pulmonary Arterial Hypertension within the First Year after DiagnosisVallerie V McLaughlin, Marius M Hoeper, David B Badesch, et al.
The New England Journal of Medicine|April 1, 2025
Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for DeathMarc Humbert, Vallerie V McLaughlin, David B Badesch, et al.
Muscle & Nerve|April 16, 2022
Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophyJeffrey M Statland, Craig Campbell, Urvi Desai, et al.
Pageof 3